Background: Hyperferritinemia has been linked to a worse prognosis in several types of cancer, and it is often seen in patients with malignancies. Objectives: The goal of this research was to learn how baseline blood ferritin levels affect prognosis among cases who had non-Hodgkin lymphoma (NHL). Patients and Methods: From May 2016 to April 2019, from the Menoufia University Clinical Oncology Department we gathered data prospectively. 77 patients with non-Hodgkin lymphoma had their clinicopathological features and serum ferritin levels evaluated. The Kaplan-Meier technique was used to calculate time to treatment failure (TTF) and overall survival (OS). Results: High serum ferritin levels were significantly associated with advanced stage, poor performance status (PS), high/ high-intermediate international prognostic index (IPI), elevated lactate dehydrogenase (LDH) and elevated β2 microglobulin in NHL (P= 0.023, P= 0.002, P= 0.001, P <0.001and P <0.001 respectively) while hyperferritinemia was significantly associated with advanced stage and elevated β2 microglobulin in HL (P =0.036 and P =0.003 respectively). No statistically significant correlations were detected between baseline ferritin levels; and response to therapy, TTF and OS in NHL patients. Conclusion: Malignant lymphoma patients whose baseline serum ferritin was high tended to have more advanced illness. However, no association between an increased ferritin level and the outcome of survival analysis was found.